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Abstract: Antisense-mediated splicing modulation is a tool that can be exploited in several 
ways to provide a potential therapy for rare genetic diseases. This approach is currently being 
tested in clinical trials for Duchenne muscular dystrophy and spinal muscular atrophy. The 
present review outlines the versatility of the approach to correct cryptic splicing, modulate 
alternative splicing, restore the open reading frame, and induce protein knockdown, providing 
examples of each. Finally, we outline a possible path forward toward the clinical application of 
this approach for a wide variety of inherited rare diseases.
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Introduction
Genetic diseases are generally rare diseases caused by mutations in specific genes. 
Sometimes mutations in different genes can give rise to similar phenotypes, eg, there 
have been dozens of genes identified in patients suffering from muscular  dystrophies.1 
However, mutations in a single gene can also give rise to multiple diseases with 
varying phenotypes. Probably the most notorious example is the LMNA gene, in 
which mutations are associated with multiple phenotypes, including Emery–Dreifuss 
muscular dystrophy, familial partial lipodystrophy, limb girdle muscular dystrophy, 
dilated cardiomyopathy, Charcot–Marie–Tooth disease, restrictive dermopathy, and 
Hutchinson–Gilford progeria syndrome (HGPS).2 For a significant number of patients 
with, or suspected of having a genetic disease, the mutation in the causative gene has 
not yet been identified. However, with the rapid advances made by “next generation 
sequencing”, it is anticipated that mutations will soon be identified for almost all 
patients with genetic disorders; the International Rare Disease Research Consortium 
(IRDiRC) has set itself an ambitious goal of having the means available to diagnose 
most rare genetic diseases by 2020 (http://www.irdirc.org).
With the availability of next generation sequencing, it is now possible to perform 
a more in-depth analysis of candidate genes. In the past, generally only exons and the 
donor and acceptor splice sites (ie, the first and last two base pairs of an intron, respec-
tively) were analyzed. However, it is now feasible to analyze complete introns and there 
are multiple publications that report deep intronic mutations that activate cryptic splice 
sites and thus disrupt normal transcript processing.3 In parallel, antisense-mediated 
splicing modulation has been developed from preclinical cell and animal models into 
the clinical trial phase for Duchenne muscular dystrophy (DMD) and spinal muscular 
atrophy (SMA).4–8 This approach makes use of antisense oligonucleotides (ASOs, small 
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pieces of chemically modified DNA or RNA) and would 
offer a potential treatment for genetic disorders caused by 
mutations that disrupt splicing, but can also be exploited in 
other ways to address genetic mutations.9 ASOs need to be 
chemically modified to improve stability to nucleases and 
provide favorable pharmacokinetic and pharmacodynamic 
characteristics for in vivo use. The most commonly used 
ASO chemistries are the 2′-O-methyl RNA phosphorothio-
ate chemistry, which is negatively charged, and the charge 
neutral phosphorodiamidate morpholino oligomer. For 
more background on ASO chemistry, we refer the reader to 
a recent book chapter.10 This review will describe different 
ways antisense-mediated splicing modulation can be used 
to treat genetic diseases. Since there are already numerous 
reviews describing exon skipping for DMD and SMA,11–14 
we have chosen to discuss these neuromuscular applications 
only briefly and to focus on the potential of the exon skipping 
approach for other genetic diseases. For each approach we 
have chosen a few illustrative examples, focusing on those 
where data from animal models is available.
Cryptic splicing
Cryptic splice sites are sequences in the pre-messenger RNA 
(pre-mRNA) that are not normally used as splice sites, but 
which are activated by mutations that either inactivate the 
canonical splice sites or create splice sites where one did 
not exist before.15 The classical example of this phenomenon 
is in the β-globin gene, where mutations in the canonical 
splice sites cause activation of cryptic splice sites, leading 
to the inclusion of aberrant exons, resulting in nonfunctional 
transcripts,  defective β-globin expression, and consequently 
β-thalassemia.16 For the majority of patients, the disease is 
caused by mutations that activate cryptic splice sites.17 In 
the early 1990s, ASOs were developed by Dominski and 
Kole using this paradigm (Figure 1A): by targeting the 
cryptic splice sites with 2′-O-methyl RNA ASOs to block 
the access of the spliceosome to these sites, their group 
was able to restore normal β-globin splicing in cells18 and 
normal hemoglobin expression, to some extent, in a thalas-
semia mouse model.19 The restoration of normal splicing 
by suppressing cryptic splicing, therefore, represents the 
very earliest manifestation of ASOs being used to modu-
late splicing for therapy. Even despite this early progress, 
clinical applications of this technology for the treatment of 
β-thalassemia have not materialized, likely as a result of the 
need to generate, validate, and trial specific ASOs for each 
type of mutation in patients, and the fact that ASO therapy 
only leads to a transient correction of splicing. As a result, 
most gene therapy research in the field has concentrated on 
viral-mediated transduction of β-globin into hematopoietic 
stem cells as a means of achieving durable and long-term 
correction of β-globin expression, with one patient achiev-
ing independence from transfusions, the usual treatment for 
β-thalassemia.20
Even though in β-thalassemia, ASO-mediated correc-
tion is being side-lined in favor of other approaches, for 
other diseases targets that could be amenable to ASO-
mediated cryptic splice site suppression continue to be 
identified. A recent example is Usher syndrome type 1C, 
characterized by congenital deafness, retinitis pigmentosa, 
and vestibular dysfunction (Figure 1B). This is caused 
by defects in the USH1C gene that encodes harmonin. 
 Harmonin is an actin-binding scaffold protein that, together 
with myosin VIIa and cadherin 23, are required to ensure 
that the stereocilia in the inner ear cohere together.21,22 The 
USH1C216G.A mutation, found in all Louisiana Acadian 
cases of Usher syndrome type 1C, creates a cryptic 5′ splice 
site within exon 3 of the gene, which is used preferentially 
over the canonical 5′ splice site, and the creation of a frame-
shift and premature truncation of the harmonin protein.23 In 
a collaborative project, Lentz et al were able to show that 
an ASO targeted to the cryptic 5′ splice site was able to 
correct the splicing of USH1C transcript, restore harmonin 
expression, and rescue cochlear hair cells, vestibular func-
tion, and hearing for at least 6 months when given to an 
animal model of USH1C216G.A.24
Alternative splicing
In humans, a myriad of proteins is responsible for most of the 
functions that form the basis of life. However, this array of dif-
ferent proteins is coded by a much (3–4-fold) smaller number 
of genes. This puzzled the field at first,25 but can be explained 
by the occurrence of alternative splicing, a mechanism that 
allows the production of several proteins from the same gene 
by means of the exclusion, inclusion, or trimming of specific 
exons. In fact, 95% of human pre-mRNA is alternatively 
spliced.26 Alternative splicing is responsible for generating 
proteins with very different, sometimes even antagonistic 
roles. Alternative splicing can also introduce stop codons that 
cause nonsense-mediated decay, and therefore, suppress the 
expression of the gene.27 In healthy individuals, this flexibility 
contributes to the clockwork functioning of human biology. 
However, aberrant alternative splicing can also be the origin 
of disease, eg, a shift from an antiproliferative isoform to 
a proproliferative isoform can underlie tumor formation. 
From the therapeutic viewpoint, this provides researchers 
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the opportunity to use ASOs as tools to knowingly shift 
alternative splicing to treat disease.
A first example involves lamin A, a nuclear envelope 
protein involved in the regulation of gene expression, nuclear 
stability, and chromatin structure that is encoded by the 
LMNA gene. A point mutation in this gene leads to a shift in 
alternative splicing,28 and increased production of progerin, 
a truncated form of lamin A that is present in small amounts 
in normal aging, but which accumulates in high levels in 
HGPS. This leads to accelerated aging and shortened life 
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Figure 1 Schematic depiction of antisense-mediated splicing modulation approaches.
Notes: (A) Restoration of cryptic splicing for β-globin mutations. Due to a mutation in intron 3, a cryptic exon is included into the β-globin mRNA, abrogating the 
production of β-globin proteins. ASOs targeting the cryptic splice sites prevent the inclusion of the cryptic exon, restoring normal splicing and production of β-globin protein. 
(B) Restoration of cryptic splicing for USH1C. Due to a mutation in exon 3, a cryptic splice site within exon 3 is activated, leading to the exclusion of the last part of the exon 
from the USCH1C transcript and loss of harmonin protein production. Using ASOs targeting the cryptic splice site in exon 3 reactivates the original splice site and restores 
normal splicing and protein production. (C) Shifting of alternative splicing. The STAT3 gene produces STAT3α and STAT3β proteins based on the use of a proximal or more 
distal acceptor splice site in exon 23 during pre-mRNA splicing. ASOs targeting the proximal acceptor splice site lead to a shift into the production of the proapoptotic 
STAT3β protein. (D) Isoform-specific knockdown. The APOB gene gives rise to APOB100 and APOB48 proteins. The latter derives from RNA editing in exon 26. Skipping 
of exon 27 gives rise to a prematurely truncated APOB protein with cholesterol-lowering properties, without affecting the APOB48 isoform.
Abbreviations: APOB, apolipoprotein B100; ASOs, antisense oligonucleotides; LDL, low-density lipoprotein; mRNA, messenger RNA; STAT3, signal transducer and 
activator of transcription 3; USH1C, Usher syndrome type 1C gene.
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span due to growth impairment, lipodystrophy, dermal and 
bone abnormalities, and cardiovascular alterations.29 This 
shift in the standard splicing of the LMNA gene favoring the 
truncated progerin protein represents an ideal example of 
how the usually firmly kept balance can be disturbed by the 
presence of this cryptic splice site: the new protein is only 
50 amino acids shorter than the original one, but lacks a vital 
target sequence for protein cleavage,30 and this in turn leads 
to the deleterious effects experienced by HGPS patients. 
A phosphorodiamidate morpholino oligomer ASO masking 
the progerin splice site has been successfully used in fibro-
blast cultures from HGPS patients to restore normal splicing 
and correct nuclear abnormalities and mislocalization of 
other nuclear envelope proteins.31 Following these advances, 
in a recent study on a murine model that recapitulates the 
main clinical signs of HGPS, vivo-morpholino ASOs were 
able to reverse many of the phenotypical alterations seen in 
these mice.32
Signal transducer and activator of transcription 3 
(STAT3) is involved in the activation of several oncogenic 
pathways. It is usually spliced to the isoform STAT3α, but an 
alternative acceptor site in exon 23 leads to the expression of 
isoform STAT3β, which lacks the C-terminal transactivation 
domain. Overexpression of STATβ can induce apoptosis and 
inhibit tumor growth. Zammarchi et al developed an ASO 
targeting a splicing enhancer site that was able to shift the 
balance of STAT3 expression to favor STAT3β expression 
(Figure 1C).33 This approach has been tested in cell and ani-
mal models and has served a double purpose: on one hand it 
allowed a detailed study of the precise functions of STAT3β 
in its physiological environment. On the other hand, ASOs 
that shift splicing to the STAT3β isoform have antitumor 
applications.
Knockdown
Exon-skipping ASOs can also be used to knockdown the 
function of an undesired gene, by inducing exon skipping 
and creating mRNA isoforms that encode nonfunctional 
proteins or trigger nonsense-mediated decay of the mRNA,34 
to inhibit the expression of the undesired gene; or encode 
alternative isoforms with desired physiological or therapeutic 
functions that could modify or antagonize the effect of an 
undesired gene. The use of exon-skipping ASOs for the first 
purpose is not generally widespread except in the special 
case of zebrafish genetics.35 Other methods, such as RNA 
interference,36 ASOs that trigger RNase H-mediated deg-
radation of mRNAs,37 or translation inhibition,38 are more 
generally used if simple knockdown is desired. An example 
of this is the knockdown of apolipoprotein B100 (APOB100) 
as a means of reducing low-density lipoprotein (LDL) secre-
tion and cholesterol levels in familial hypercholesterolemia.39 
Both RNase H “gap-mer” ASOs and RNA interference have 
been used for this purpose, reducing LDL cholesterol in 
vivo.40,41 These simple knockdown approaches, however, have 
the undesired effect of knocking down the APOB48 isoform, 
and therefore reduce chylomicron secretion.42 This will inter-
fere with fat transport from the intestine and malabsorption 
of fat-soluble vitamins such as vitamin K.43
Exon-skipping ASOs offer a distinct advantage over 
simple knockdown, as engineered alternative isoforms may 
possess their own therapeutic properties, inhibit the function 
of a normal isoform, and/or avoid side effects of knockdown 
of the normal isoform. Capitalizing on this advantage, exon-
skipping exon 27 of the APOB gene using ASOs causes a 
reduction of LDL particle secretion and an increase in LDL 
affinity for the LDL receptor (Figure 1D).44 These two effects 
combine to cause a powerful reduction of LDL cholesterol 
when the “APO-skip” ASOs are introduced into hypercho-
lesterolemic mice transgenic for human APOB, validating the 
therapeutic concept.45 Importantly, exon 27 skipping does not 
affect APOB48 expression, as the RNA editing necessary for 
APOB48 expression occurs in exon 26.45 In this example, 
therefore, exon-skipping technology enables the reengineer-
ing of gene expression to produce a desired outcome with 
clear therapeutic advantages over other approaches to the 
same problem.
Reading frame correction
The coding sequence for proteins is dispersed over exons, and 
the location where introns interrupt the code can be in three 
phases in relation to the coding sequence: either between 
complete codons (phase 0 introns), interrupting after the first 
nucleotide of the codon (phase 1 introns), or interrupting after 
the second nucleotide of the codon (phase 2 introns). As this 
will apply to both the beginning and the end of each exon, 
each exon will have two jigsaw-like ends that will require a 
complementary exon before and after to maintain the open 
reading frame (ORF).46 Therefore, a symmetrical exon can be 
deleted without interrupting the ORF, but others, if deleted, 
would cause a disruption in the ORF (Figure 2). For most 
genes, the deletion of an exon would result in a nonfunctional 
protein regardless of whether the ORF is disrupted by the 
deletion, since the majority of proteins do not have redundant 
domains. However, there are some exceptions where deletions 
that maintain the ORF allow the production of internally 
deleted but partially functional proteins. This concept is best 
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illustrated in the neuromuscular disorder DMD, an early 
onset, severely progressive muscle-wasting disorder.47 In the 
majority of DMD patients, deletions or duplications of one or 
more exons cause a disruption of the ORF and the deficit of 
its encoded protein, dystrophin.48 In a stark contrast to DMD, 
another disorder in which one or more exons are also deleted 
from the DMD gene, Becker muscular dystrophy, has a much 
milder progression. The difference is that in Becker patients, 
the deletions do not disrupt the ORF and a shorter, but partially 
functional dystrophin protein is produced.48 The existence of 
Becker muscular dystrophy is the conceptual basis for the 
model of exon skipping: ASOs are used to “mask” specific 
exons to the splicing machinery to restore the ORF and partial 
dystrophin function for DMD patients.
From early proof of concept experiments to the latest clin-
ical trials, the developments in the use of ASOs as a potential 
therapeutic agent in DMD have been fast: restoration of 
dystrophin has been achieved following intramuscular49,50 
and systemic4,5,51 injections of ASOs targeting DMD exon 51, 
and these and several other ASOs targeting other exons are 
progressing through clinical trials.52
SMA, the most common genetic cause of death in 
infants under the age of 2 years, is caused by deletions and 
mutations of SMN1, and consequently low levels of SMN 
protein, a ubiquitously expressed protein involved in RNA 
processing.53 Although a duplicate of SMN1, SMN2 also 
exists within the genome and also encodes SMN; it is usually 
inefficiently spliced due to minor differences in and around 
exon 7. As a result, only 20% of SMN2 mRNA transcripts 
include exon 7, which is necessary for the stability of SMN 
protein.54 In healthy individuals, this is irrelevant, but in 
SMA patients, increasing the amount of exon 7 inclusion 
from SMN2 transcripts could allow the generation of suffi-
cient amounts of SMN protein to ameliorate their disease. In 
fact, several studies using ASOs have already demonstrated 
in vitro and in vivo that this is possible,6,55–58 and clinical 
trials are underway.
Toward clinical application
From the above, it is clear that antisense-mediated splicing 
modulation may offer a potential treatment for rare inherited 
diseases, and as such, can be seen as a platform approach. 
For DMD and SMA, the approach has made it to the clini-
cal trial phase, whereas other genetic diseases are still in 
preclinical development. While each of these diseases will 
have their own quirks and challenges (eg, delivery to the tar-
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Figure 2 effect of exon deletions on the open reading frame.
Notes: (A) Different ways in which codons in exons may be split by introns: in phase 0 introns, the codon ends at the end of the exon, while in phase 1 and phase 2 introns 
the codon is split over the 2 exons, with the interruption after the first or the second nucleotide of the codon, respectively. (B) As each exon is separated from the next and 
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would have no effect on the reading frame (in-frame), while others will disrupt it (out-of-frame).
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get tissue and dosing regimens will vary between diseases), 
there will be common challenges and hurdles as well, since 
they all use the exon-skipping platform. Furthermore, 
there is no reason why people embarking on developing 
exon skipping for their disease of choice should have to 
repeat mistakes others have made in the past. Therefore, 
networking between scientists involved in this endeavor 
is warranted. The European Cooperation of Science and 
Technology (COST) provides funding for networking to 
overcome challenges such as these, and has funded the 
Action “Networking towards clinical application of anti-
sense-mediated exon skipping for rare diseases” (BM1207, 
see http://www.cost.eu and http://www.exonskipping.eu).59 
Within this Action, regular workshops are organized to 
discuss common challenges, such as delivery to the target 
tissue, ASO chemistry and safety, and to align preclinical 
work. Furthermore, the Action focuses on the development 
of new regulatory models and has recently had a workshop 
on translational and regulatory challenges with representa-
tives from patient organizations, academia, and regulatory 
agencies,60 following a larger workshop organized by the 
Translational Research in Europe – Assessment and Treat-
ment of Neuromuscular Diseases (TREAT-NMD) network 
and hosted by the European Medicines Agency that focused 
on the particulars of exon skipping for DMD.61
One of the key factors for clinical development will be 
the harmonization of outcome measures. While the regulators 
will provide market approval only when clinically relevant 
benefit has been convincingly shown, biochemical out-
come measures can provide additional information, eg, by 
 confirming mechanism of action of ASOs. Lessons could be 
learned from the case of DMD: when the first clinical trials 
using ASOs were outlined, methods to measure dystrophin 
restoration relied heavily on standard clinical diagnostic 
techniques and academic protocols, and each research cen-
ter used their own version of the methods.4,5,49,51,52 The most 
commonly used method was immunofluorescent staining, but 
the large size and low expression level of the protein made 
accurate quantification technically challenging, especially 
when the amount of restored dystrophin is relatively small 
and it needs to be distinguished from preexisting dystrophin-
positive revertant fibers and residual trace dystrophin expres-
sion.52,62 To overcome some of those difficulties, refinements 
developed, in particular using better software analysis.63,64 
A group of laboratories from academia and industry have 
embarked on an effort to provide a data-driven reproducible 
 methodology for dystrophin quantification that could be 
used in future  trials. This group has revised methodologies, 
validated them among their laboratories, and proposed a 
standard operating procedure.52,65
Conclusion
ASO-mediated splicing modulation holds potential for 
treating rare genetic diseases as outlined in this review, and 
as corroborated by the advances made for DMD and SMA. 
International networks on exon skipping aim to help sci-
entists developing this approach for other diseases benefit 
from the experience gained from the DMD field, to jointly 
overcome challenges and further this approach toward 
clinical application for as many rare genetic diseases as 
possible.
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